Medarex, BMS Stall Ipilimumab’s BLA
This article was originally published in The Pink Sheet Daily
Executive Summary
Timing for melanoma drug is uncertain after talks with FDA.
You may also be interested in...
Medarex/BMS Working To Shift Ipilimumab Trial Endpoint
Overall survival is more valid than freedom from progression in Phase III melanoma trial, firm says.
Medarex/BMS Working To Shift Ipilimumab Trial Endpoint
Overall survival is more valid than freedom from progression in Phase III melanoma trial, firm says.
GSK/Synta Elesclomol Analysis Shows Stronger Benefit In Treatment Naive Patients
Data is the basis for Phase III study design, with filing targeted for 2009.